These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 8794983)
61. Bioavailability study of two different 8-methoxypsoralen (8-MOP) preparations in patients receiving PUVA therapy. Nørgaard M; Hueg B; Staberg B Photodermatol; 1985 Aug; 2(4):252-6. PubMed ID: 3903679 [TBL] [Abstract][Full Text] [Related]
62. The pharmacokinetics of 8-methoxypsoralen following i.v. administration in humans. Billard V; Gambus PL; Barr J; Minto CF; Corash L; Tessman JW; Stickney JL; Shafer SL Br J Clin Pharmacol; 1995 Oct; 40(4):347-60. PubMed ID: 8554937 [TBL] [Abstract][Full Text] [Related]
63. Efficacy of bath psoralen plus ultraviolet A (PUVA) vs. system PUVA in psoriasis: a prospective, open, randomized, multicentre study. Berneburg M; Herzinger T; Rampf J; Hoetzenecker W; Guenova E; Meisner C; Maetzke J; Schaefer T; Eberlein B; Scharffetter-Kochanek K; Rocken M Br J Dermatol; 2013 Sep; 169(3):704-8. PubMed ID: 23772997 [TBL] [Abstract][Full Text] [Related]
64. Plasma and buffy coat concentration of 8-methoxypsoralen in patients treated with extracorporeal photopheresis. Balogh A; Merkel U; Looks A; Vollandt R; Wollina U Exp Toxicol Pathol; 1998 Sep; 50(4-6):397-401. PubMed ID: 9784014 [TBL] [Abstract][Full Text] [Related]
65. The active compounds derived from Psoralea corylifolia for photochemotherapy against psoriasis-like lesions: The relationship between structure and percutaneous absorption. Alalaiwe A; Hung CF; Leu YL; Tahara K; Chen HH; Hu KY; Fang JY Eur J Pharm Sci; 2018 Nov; 124():114-126. PubMed ID: 30153523 [TBL] [Abstract][Full Text] [Related]
66. The role of stratum corneum and dermal microvascular perfusion in penetration and tissue levels of water-soluble drugs investigated by microdialysis. Morgan CJ; Renwick AG; Friedmann PS Br J Dermatol; 2003 Mar; 148(3):434-43. PubMed ID: 12653734 [TBL] [Abstract][Full Text] [Related]
67. Bath-water PUVA therapy with 8-methoxypsoralen in mycosis fungoides. Weber F; Schmuth M; Sepp N; Fritsch P Acta Derm Venereol; 2005; 85(4):329-32. PubMed ID: 16191854 [TBL] [Abstract][Full Text] [Related]
68. 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo. McNeely W; Goa KL Drugs; 1998 Oct; 56(4):667-90. PubMed ID: 9806110 [TBL] [Abstract][Full Text] [Related]
69. Effect of physicochemical properties of cyclic terpenes on their ex vivo skin absorption and elimination kinetics. Cal K; Kupiec K; Sznitowska M J Dermatol Sci; 2006 Feb; 41(2):137-42. PubMed ID: 16260121 [TBL] [Abstract][Full Text] [Related]
70. Drug monitoring of orally administered 8-methoxypsoralen in patients treated with extracorporeal photopheresis. Balogh A; Merkel U; Looks A; Vollandt R; Wollina U Skin Pharmacol Appl Skin Physiol; 1998; 11(4-5):258-65. PubMed ID: 9885410 [TBL] [Abstract][Full Text] [Related]
71. Plasma levels of 8-methoxypsoralen after topical paint PUVA. Pham CT; Koo JY J Am Acad Dermatol; 1993 Mar; 28(3):460-6. PubMed ID: 8445063 [TBL] [Abstract][Full Text] [Related]
72. UVA irradiation following treatment with topical 8-methoxypsoralen improves bleomycin-induced scleroderma in a mouse model, by reducing the collagen content and collagen gene expression levels in the skin. Hayashi S; Ikeda M; Kitamura Y; Hamasaki Y; Hatamochi A J Dermatol Sci; 2012 Jul; 67(1):20-5. PubMed ID: 22486844 [TBL] [Abstract][Full Text] [Related]
73. Can the immersion time of PUVA bath therapy be shortened? Schiener R; Behrens-Williams SC; Pillekamp H; Kaskel P; Peter RU; Kerscher M Acta Derm Venereol; 2002; 82(1):18-20. PubMed ID: 12013191 [TBL] [Abstract][Full Text] [Related]
74. [8-methoxypsoralen serum content of problem patients in PUVA therapy]. Walther T; Haustein UF Dermatol Monatsschr; 1990; 176(5-6):317-21. PubMed ID: 2227049 [TBL] [Abstract][Full Text] [Related]
75. Bath PUVA and psoriasis: is a milder treatment a worse treatment? Delrosso G; Bornacina C; Farinelli P; Bellinzona F; Leigheb G; Colombo E Dermatology; 2008; 216(3):191-3. PubMed ID: 18182808 [TBL] [Abstract][Full Text] [Related]
76. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. Archier E; Devaux S; Castela E; Gallini A; Aubin F; Le Maître M; Aractingi S; Bachelez H; Cribier B; Joly P; Jullien D; Misery L; Paul C; Ortonne JP; Richard MA J Eur Acad Dermatol Venereol; 2012 May; 26 Suppl 3():22-31. PubMed ID: 22512677 [TBL] [Abstract][Full Text] [Related]
77. Probing the permeation enhancement of mefenamic acid by ethanol across full-thickness skin, heat-separated epidermal membrane and heat-separated dermal membrane. Heard CM; Screen C Int J Pharm; 2008 Feb; 349(1-2):323-5. PubMed ID: 17870262 [TBL] [Abstract][Full Text] [Related]
78. Paired comparison of bathwater versus oral delivery of 8-methoxypsoralen in psoralen plus ultraviolet: A therapy for chronic palmoplantar psoriasis. Hofer A; Fink-Puches R; Kerl H; Quehenberger F; Wolf P Photodermatol Photoimmunol Photomed; 2006 Feb; 22(1):1-5. PubMed ID: 16436174 [TBL] [Abstract][Full Text] [Related]
79. Standardizing 8-methoxypsoralen plasma profiles by using an emulsion form. Van Boven M; Roelandts R; Adriaens P; Daenens P; Degreef H; Kinget R J Am Acad Dermatol; 1985 May; 12(5 Pt 1):822-7. PubMed ID: 4008686 [TBL] [Abstract][Full Text] [Related]
80. Effect of chemical interactions in pentachlorophenol mixtures on skin and membrane transport. Baynes RE; Brooks JD; Mumtaz M; Riviere JE Toxicol Sci; 2002 Oct; 69(2):295-305. PubMed ID: 12377978 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]